Inhibition of phosphodiesterase 4 by FCPR16 protects SH-SY5Y cells against MPP(+)-induced decline of mitochondrial membrane potential and oxidative stress

Phosphodiesterase 4 (PDE4) is a promising target for the treatment of Parkinson's disease (PD). However, the underlying mechanism has not yet been well elucidated. Additionally, most of current PDE4 inhibitors produce severe nausea and vomiting response in patients, which limit their clinical a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jiahong, Yu, Hui, Huang, Chang, Zhong, Qiuping, Chen, Yaping, Xie, Jinfeng, Zhou, Zhongzhen, Xu, Jiangping, Wang, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842311/
https://www.ncbi.nlm.nih.gov/pubmed/29475134
http://dx.doi.org/10.1016/j.redox.2018.02.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5842311/
https://www.ncbi.nlm.nih.gov/pubmed/29475134
http://dx.doi.org/10.1016/j.redox.2018.02.008

Ejemplares similares